IL234779A - Intracellular markers for Alzheimer's detection and monitoring of disease progression - Google Patents
Intracellular markers for Alzheimer's detection and monitoring of disease progressionInfo
- Publication number
- IL234779A IL234779A IL234779A IL23477914A IL234779A IL 234779 A IL234779 A IL 234779A IL 234779 A IL234779 A IL 234779A IL 23477914 A IL23477914 A IL 23477914A IL 234779 A IL234779 A IL 234779A
- Authority
- IL
- Israel
- Prior art keywords
- alzheimer
- disease
- diagnosis
- cellular markers
- disease progression
- Prior art date
Links
- 208000024827 Alzheimer disease Diseases 0.000 title 2
- 230000001413 cellular effect Effects 0.000 title 1
- 238000003745 diagnosis Methods 0.000 title 1
- 230000005750 disease progression Effects 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Virology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261615465P | 2012-03-26 | 2012-03-26 | |
| PCT/IL2013/050277 WO2013144957A1 (en) | 2012-03-26 | 2013-03-21 | Cellular markers for diagnosis of alzheimer's disease and for alzheimer's disease progression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL234779A true IL234779A (en) | 2017-12-31 |
Family
ID=49258360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL234779A IL234779A (en) | 2012-03-26 | 2014-09-22 | Intracellular markers for Alzheimer's detection and monitoring of disease progression |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20150057176A1 (enExample) |
| EP (1) | EP2831584B1 (enExample) |
| JP (1) | JP6276252B2 (enExample) |
| KR (1) | KR20140145173A (enExample) |
| CN (1) | CN104471394B (enExample) |
| AU (1) | AU2013239070A1 (enExample) |
| CA (1) | CA2907909A1 (enExample) |
| ES (1) | ES2819174T3 (enExample) |
| IL (1) | IL234779A (enExample) |
| WO (1) | WO2013144957A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6312302B2 (ja) * | 2014-01-06 | 2018-04-18 | 公益財団法人ヒューマンサイエンス振興財団 | 脳梗塞の診断マーカー |
| US12227567B2 (en) | 2017-07-25 | 2025-02-18 | Truebinding, Inc. | Treating cancer by blocking the interaction of TIM-3 and its ligand |
| JP6499342B2 (ja) * | 2018-03-19 | 2019-04-10 | 隆樹 日和佐 | 脳梗塞の診断マーカー |
| CN116063520A (zh) | 2019-01-30 | 2023-05-05 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| WO2020198299A1 (en) * | 2019-03-26 | 2020-10-01 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for characterizing and treating alzheimer's disease |
| CN111727260A (zh) * | 2019-10-15 | 2020-09-29 | 湖南乾康科技有限公司 | 中间型单核细胞在制备诊断和预测ad药物中的应用 |
| CN116157151A (zh) | 2020-05-26 | 2023-05-23 | 真和制药有限公司 | 通过阻断半乳凝素-3治疗炎性疾病的方法 |
| CN112562867A (zh) * | 2021-02-22 | 2021-03-26 | 天津迈德新医药科技有限公司 | 一种预测极早期hiv感染风险的装置、存储介质和电子装置 |
| EP4426295A1 (en) * | 2021-11-02 | 2024-09-11 | Tranquis Therapeutics, Inc. | Selection and treatment of subjects having a circulating myeloid cell inflammatory phenotype |
| KR102745500B1 (ko) * | 2022-09-02 | 2024-12-23 | 한양대학교 에리카산학협력단 | 혈액 대사체를 이용한 치매 스크리닝 장치 및 방법 |
| CN116270741B (zh) * | 2023-02-28 | 2025-10-24 | 东莞市东南部中心医院 | 骨髓源性抑制细胞在制备治疗阿兹海默症药物或试剂中的应用 |
| CN117122612B (zh) * | 2023-07-07 | 2024-08-27 | 河络新图生物科技(上海)有限公司 | 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1248643E (pt) * | 2000-01-20 | 2005-10-31 | Yeda Res & Dev | Utilizacao de copolimero 1 e peptidos e polipeptidos congeneres e de celulas t tratadas co estes compostos para terapia neuroprotectora |
| US20020137108A1 (en) * | 2000-11-08 | 2002-09-26 | Michael Mullan | CD45 isoform alteration in CD4+ T cells as a potential diagnostic marker in alzheimer's disease |
| KR20040081431A (ko) * | 2001-12-06 | 2004-09-21 | 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 | 운동신경 질환의 치료용 백신 및 치료 방법 |
| ES2350895T3 (es) * | 2004-08-19 | 2011-01-28 | University College Cardiff Consultants Limited | Preparación de células t gamma delta humanas presentadoras de antígeno y su uso en inmunoterapia. |
| MX349711B (es) * | 2008-09-18 | 2017-08-09 | Cedars Sinai Medical Center | Método óptico para la detección de la enfermedad de alzheimer. |
| CA2792471A1 (en) | 2010-03-10 | 2011-09-15 | Yeda Research And Development Co. Ltd | Cellular blood markers for early diagnosis of als and for als progression |
-
2013
- 2013-03-21 US US14/388,369 patent/US20150057176A1/en not_active Abandoned
- 2013-03-21 EP EP13767635.9A patent/EP2831584B1/en active Active
- 2013-03-21 CN CN201380027520.5A patent/CN104471394B/zh active Active
- 2013-03-21 ES ES13767635T patent/ES2819174T3/es active Active
- 2013-03-21 WO PCT/IL2013/050277 patent/WO2013144957A1/en not_active Ceased
- 2013-03-21 KR KR1020147029916A patent/KR20140145173A/ko not_active Withdrawn
- 2013-03-21 AU AU2013239070A patent/AU2013239070A1/en not_active Abandoned
- 2013-03-21 JP JP2015502555A patent/JP6276252B2/ja active Active
- 2013-03-21 CA CA2907909A patent/CA2907909A1/en not_active Abandoned
-
2014
- 2014-09-22 IL IL234779A patent/IL234779A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140145173A (ko) | 2014-12-22 |
| JP6276252B2 (ja) | 2018-02-07 |
| WO2013144957A1 (en) | 2013-10-03 |
| US20150057176A1 (en) | 2015-02-26 |
| CA2907909A1 (en) | 2013-10-03 |
| CN104471394A (zh) | 2015-03-25 |
| JP2015511721A (ja) | 2015-04-20 |
| AU2013239070A1 (en) | 2014-11-13 |
| EP2831584A4 (en) | 2015-10-07 |
| CN104471394B (zh) | 2017-04-05 |
| EP2831584B1 (en) | 2020-06-17 |
| ES2819174T3 (es) | 2021-04-15 |
| EP2831584A1 (en) | 2015-02-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL234779A (en) | Intracellular markers for Alzheimer's detection and monitoring of disease progression | |
| IL237369A0 (en) | Methods for treating Alzheimer's disease and pharmaceutical compositions thereof | |
| EP2932296A4 (en) | PICTURING SUB-SURFACE RADAR | |
| IL239025A0 (en) | Treatment of lung disease | |
| EP2934282A4 (en) | LOCATION OF INTRAVASCULAR PICTURES | |
| EP2628013A4 (en) | BIOMARKER FOR BRAIN INJURY | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| IL230034B (en) | MicroRNA biomarkers that indicate Alzheimer's disease | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| EP2819610A4 (en) | DETERMINATION OF ANATOMICAL EQUIPMENT | |
| IL230441A0 (en) | Diagnosis of Alzheimer's disease | |
| EP2934378A4 (en) | CATHETER ORIENTATION MARKER | |
| EP2899580A4 (en) | LENS FOR ENDOSCOPE-LENS | |
| GB201310150D0 (en) | Methods and compositions relating to alzheimer's disease | |
| IL234606A0 (en) | Innovative methods and compounds for the treatment of diseases | |
| GB201206382D0 (en) | Parkinson's disease biomarker | |
| IL237730B (en) | Treatment of mild and moderate Alzheimer's disease | |
| SG11201503129RA (en) | Levodopa formulations for rapid relief of parkinson's disease | |
| GB201310203D0 (en) | Materials and methods relating to Alzheimer's disease | |
| AP2014007905A0 (en) | Novel compounds for the treatment of dyslipidemia and related diseases | |
| EP2934285A4 (en) | METHOD AND SYSTEMS FOR DIAGNOSIS OF EYE DISEASES | |
| ZA201402477B (en) | Compounds for use in the treatment of alzheimer's disease | |
| SG10201801200PA (en) | An h3 receptor antagonist for use in the treatment of alzheimer's disease | |
| GB201204014D0 (en) | Diagnostic marker compounds and their use | |
| GB201311036D0 (en) | Biomarkers for alzheimer's Disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed |